口服多肽向FDA递交上市申请 药明康德共同强生等参与

银柿财经
22 Jul

据药明康德(603259.SH)官微7月22日消息,药明康德共同强生(Johnson & Johnson)与Protagonist Therapeutics今日宣布,已向美国FDA提交新药申请(NDA),寻求批准其在研、每日一次口服多肽疗法icotrokinra(JNJ-2113)上市,用于治疗12岁及以上中度至重度斑块状银屑病(PsO)成人与儿科患者。值得一提的是,它曾在今年4月被知名产业媒体...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10